- CDC News
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Clinical Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Anemia
- Neurology
- Pulmonology
Assessing the Burden of Type 1 Diabetes
Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.
The following transcript has been edited for clarity and length.
Dr. Javier Morales: Hi, and greetings. Thank you so much for joining us on Patient Care Frontline Insights. Today's presentation is titled, "Ahead of the Curve: Early Interventions for Delaying Type 1 Diabetes." I’m Javier Morales, an internist from Long Island and Associate Clinical Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell.
I'm delighted to be joined by an esteemed panel: Dr David Robertson, from Atlanta Diabetes Associates, in Atlanta, GA; Dr Shira Eytan, an endocrinologist at Park Avenue Endocrinology and Nutrition in New York City; and Andrea Stallings, a physician’s assistant from the University of California San Diego Health-La Jolla and Hillcrest Hospitals. Thank you all for joining us.
Our objectives today include the following:
• Highlight the Core Objectives of National Diabetes Month: Emphasize the goals of National Diabetes Month to increase awareness and focus on delaying and managing type 1 diabetes through early intervention and proactive health care strategies.
• Importance of Screening for Type 1 Diabetes: Emphasize the role of early screening, including the screening process, available tools, screening selection criteria, and the potential to delay disease progression through timely intervention.
• Increase Awareness of Type 1 Diabetes Staging: Improve health care professionals’ understanding of the stages of T1D and the impact of early intervention, specifically the role of teplizumab in delaying disease progression.
• Navigating the Treatment Process with Teplizumab: Guide health care providers in securing teplizumab approval, establishing effective referral networks, and managing the 14-day infusion process, including location and timing considerations for optimal patient experience.
• Optimizing Patient Outcomes in Type 1 Diabetes: Equip health care providers with strategies to improve patient quality of life by identifying at-risk individuals, ensuring timely access to teplizumab, and reducing complications like diabetic ketoacidosis (DKA).
To start, let’s engage with a question: Who do you believe constitutes primary populations at increased risk for developing T1D?
Your options are:
A. Children and adolescents
B. Adults over 30 years old
C. Individuals with a family history of T1D
D. People with autoimmune conditions
E. None of the above
Take a moment to answer.
The results are divided, but we know that children, adults aged over 30 years, individuals with a family history of type 1 diabetes, and those with autoimmune conditions are all at increased risk. This emphasizes the need for targeted screening. Andrea Stallings will now lead the first segment of today’s discussion. Andrea, take it away.
Dr. Andrea Stallings: Thank you, Dr Morales. I work in adult endocrinology, and one of the trends that we’ve been seeing is a rising incidence of type 1 diabetes across all age groups. Annually, 64 000 people are diagnosed with type 1 diabetes in the US alone. While type 1 diabetes can develop at any age, having a first-degree family member with type 1 diabetes increases the risk significantly—from 1 in 300 in the general population to 1 in 20. That is a 15% increased risk of developing type 1 diabetes. November 14th marks World Diabetes Day, part of a global awareness campaign. Over the next 3 years, the focus is on fostering collaboration and identifying those at risk for both type 1 and type 2 diabetes.
Patients with diabetes face enormous burdens—not only physical but emotional and financial. This is particularly true for type 1 diabetes, which requires intensive daily management. Educating patients when they are well can empower them to live healthier lives and potentially delay disease onset. Early intervention and education are critical.
Morales: Thank you, Andrea. Your points about the burdens of diabetes are well taken. While much of the focus has traditionally been on type 2 diabetes, screening and early action in type 1 diabetes are vital because we now have effective strategies to delay progression.
Stallings: Absolutely. A patient-centered approach is key. By educating patients about their condition and involving them in their care, we can improve adherence and outcomes. This requires a team effort involving nurses, advanced practice providers, and certified diabetes educators.
Morales: Exactly. Managing diabetes effectively isn’t just the clinician’s responsibility. Pharmacists, physical therapists, and other allied health care professionals play critical roles in supporting patients. Collaborative care is essential for achieving optimal outcomes.
Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?
May 8th 2013The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?
